Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Carcinoma, Renal Cell 2Pathologic Complete Response 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × lentiviral minigene vaccine of COVID-19 coronavirus × Clear all
NCT02334735 2022-09-15

A Comparison of Matured Dendritic Cells and MontanideĀ® in Study Subjects With High Risk of Melanoma Recurrence

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
36 enrolled
Dermatologic

Melanoma

NCT01876212 2019-08-22

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

University of Pittsburgh

Phase 2 Completed
15 enrolled 26 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔